Company Description

MISO Chip's preclinical platform enables the ex vivo testing of anticancer agents on human tumors with their native tumor microenvironment (TME) preserved. They help biotech and pharmaceutical companies make better decisions by leveraging our patient-derived tumor model before they enter the clinic.